SEC Form 4 · accession 0001209191-18-035033
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian T Clark
Director
Period of report
May 31, 2018
Accepted (ET)
Jun 4, 2018 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $93.50 | May 31, 2018 | A | 5,700 | A | — | May 30, 2028 | Common stock | 5,700 | 5,700 | D |
| Restricted stock unitsF2,F3 | — | May 31, 2018 | A | 1,400 | A | — | — | Common stock | 1,400 | 1,400 | D |
Explanation of responses
- F1This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019.
- F2Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F3The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.